Bertino EM, Gentzler RD, Clifford S, Kolesar J, et al. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res 2021;27:1604-1611.
PMID: 33376097